Short communication: Selective cytotoxicity of curcumin on osteosarcoma cells compared to healthy osteoblasts

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 461-465

  Chang, Run ^a   Sun, Linlin ^a   Webster, Thomas J ^a,b  

^a Northeastern University   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Bone cancer; Curcumin; Human osteoblast; Osteosarcoma; Viability

Indexed keywords

CURCUMIN; DIMETHYL SULFOXIDE; NANOPARTICLE; PLACEBO;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DENSITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOSARCOMA;

BONE CANCER; CURCUMIN; HUMAN OSTEOBLAST; OSTEOSARCOMA; VIABILITY;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSTEOBLASTS; OSTEOSARCOMA;

EID: 84892406282     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55505     Document Type: Article

References (15)

1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(7):vii320-vii325.
2. Chow W, Haglund K, Randall RL. Bone sarcomas [webpage on the Internet]. Cancer Network; 2013 [updated May 15, 2013]. Available from: http://www.cancernetwork.com/cancer-management/bone-sarcomas. Accessed November 20, 2013.
3. McTiernan A, Jinks RC, Sydes MR, etal. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer. 2012;48(5):703-712.
4. Tennesen HH, Greenhill JV. Studies on curcumin and curcuminoids. XXII: curcumin as a reducing agent and as a radical scavenger. Int J Pharm. 1992;87(1-3):79-87.
5. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12.
6. Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-jB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res. 2004;14(3):165-171.
7. Jin S, Xu HG, Shen JN, Chen XW, Wang H, Zhou JG. Apoptotic effects of curcumin on human osteosarcoma U2OS cells. Orthop Surg. 2009;1(2):144-152.
8. Khaw AK, Hande MP, Kalthur G, Hande MP. Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells. J Cell Biochem. 2013;114(6):1257-1270.
9. Chan WH, Wu HY, Chang WH. Dosage effects of curcumin on cell death types in a human osteoblast cell line. Food Chem Toxicol. 2006;44(8):1362-1371.
10. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10(3):511-545.
11. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2013;4(6):807-818.
12. Kumar A, Ahuja A, Ali J, Baboota S. Conundrum and therapeutic potential of curcumin in drug delivery. Crit Rev Ther Drug Carrier Syst. 2010;27(4):279-312.
13. Song Z, Feng R, Sun M, etal. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci. 2011;354(1):116-123.
14. Altunbas A, Lee SJ, Rajasekaran SA, Schneider JP, Pochan DJ. Encapsulation of curcumin in self-assembling peptide hydrogels as injectable drug delivery vehicles. Biomaterials. 2011;32(25): 5906-5914.
15. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1-2):155-163.